Mathai Mammen, J&J EVP of pharmaceuticals, R&D (Rob Tannenbaum)
December 9, 2021 08:19 AM ESTUpdated December 10, 02:31 PM
People
Bioregnum
Pharma

Promis­ing to slim down and speed up, the ‘new’ J&J shakes up the ex­ec­u­tive com­mit­tee ahead of the big split

The new J&J has a fresh cor­po­rate face to show the pub­lic — sev­er­al in fact.

As the health­care con­glom­er­ate fol­lows a now fa­mil­iar phar­ma path …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times